Skip to main content
. Author manuscript; available in PMC: 2018 Jan 23.
Published in final edited form as: N Engl J Med. 2016 Nov 13;376(1):41–51. doi: 10.1056/NEJMoa1609243

Figure 2. Effects on Serum Levels of Low-Density Lipoprotein (LDL) Cholesterol, According to Study Group and Dose Cohort.

Figure 2

Shown are the effects (mean percentage changes from baseline) of inclisiran or placebo on the serum levels of LDL cholesterol over time. Baseline values were the average of all the study measurements taken before the first dose. For the single-dose cohorts, the data for the placebo group include all the participants; for the multiple-dose cohorts, the data for the placebo group are presented according to whether the participants were or were not taking a stable baseline dose of statin cotherapy. I bars represent standard errors. For at least one cohort, only one value (for one participant) is shown at some time points. In the single-dose phase, inclisiran or placebo was administered in one dose on day 0. In the multiple-dose phase, the first dose was administered on day 0 and subsequent doses at the indicated intervals. The 300-mg and 500-mg doses were administered as two monthly doses, the 125-mg dose was administered as four weekly doses, and the 250-mg dose was administered once every 2 weeks for two doses.